MEDP in the 13F filings
Medpace HLDGS Inc · CUSIP 58506Q109
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 16 Sep 2024
- latest of these filings; the earliest 25 Jul 2024
- Managers listing it
- 18
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 15 listed it in both
- Shares listed
- 3,082,319
- combined, among listed positions
- Reported value
- $1.3bn
- combined, at the quarter end
Among the 94 comparable managers: 9 buyers (opened or added shares) and 9 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing MEDP in Q2 2024
18 of 18 holders
Largest increases and reductions, by shares
Increases
- Renaissance Technologies LLCexisting position · 443,588 shares now+122,800
- AQR Capital Management LLCexisting position · 310,650 shares now+119,257
- Point72 Asset Management LPnew position · 62,432 shares now+62,432
- Two Sigma Investments LPexisting position · 123,797 shares now+46,297
- Two Sigma Advisers LPexisting position · 180,300 shares now+29,500
Reductions
- D. E. Shaw & Co.existing position · 299,865 shares now-72,214
- Voloridge Investment Management LLCexisting position · 122,478 shares now-46,069
- Arrowstreet Capital LPexisting position · 237,349 shares now-13,649
- Wellington Management Group LLPexisting position · 305,369 shares now-12,534
- Invesco Ltdexisting position · 806,975 shares now-8,826
New positions and exits
New (2)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 2 | $21m | n.a. | n.a. |
| Q2 2017 | 1 | $14m | n.a. | n.a. |
| Q3 2017 | 1 | $19m | n.a. | n.a. |
| Q4 2017 | 1 | $23m | n.a. | n.a. |
| Q1 2018 | 3 | $37m | n.a. | n.a. |
| Q2 2018 | 4 | $59m | n.a. | n.a. |
| Q3 2018 | 14 | $247m | n.a. | n.a. |
| Q4 2018 | 6 | $119m | n.a. | n.a. |
| Q1 2019 | 4 | $100m | n.a. | n.a. |
| Q2 2019 | 4 | $117m | n.a. | n.a. |
| Q3 2019 | 6 | $140m | n.a. | n.a. |
| Q4 2019 | 5 | $122m | n.a. | n.a. |
| Q1 2020 | 7 | $144m | n.a. | n.a. |
| Q2 2020 | 8 | $173m | n.a. | n.a. |
| Q3 2020 | 12 | $218m | n.a. | n.a. |
| Q4 2020 | 8 | $187m | n.a. | n.a. |
| Q1 2021 | 9 | $153m | n.a. | n.a. |
| Q2 2021 | 8 | $156m | n.a. | n.a. |
| Q3 2021 | 11 | $413m | n.a. | n.a. |
| Q4 2021 | 12 | $668m | n.a. | n.a. |
| Q1 2022 | 6 | $107m | n.a. | n.a. |
| Q2 2022 | 5 | $97m | n.a. | n.a. |
| Q3 2022 | 3 | $59m | n.a. | n.a. |
| Q4 2022 | 10 | $269m | n.a. | n.a. |
| Q1 2023 | 14 | $275m | n.a. | n.a. |
| Q2 2023 | 17 | $468m | n.a. | n.a. |
| Q3 2023 | 15 | $378m | n.a. | n.a. |
| Q4 2023 | 14 | $501m | 8 | 7 |
| Q1 2024 | 17 | $1.2bn | 9 | 8 |
| Q2 2024 | 18 | $1.3bn | 9 | 9 |
| Q3 2024 | 15 | $918m | 9 | 6 |
| Q4 2024 | 15 | $1.2bn | 9 | 6 |
| Q1 2025 | 12 | $986m | 11 | 1 |
| Q2 2025 | 14 | $1.2bn | 12 | 3 |
| Q3 2025 | 17 | $1.9bn | 9 | 8 |
| Q4 2025 | 14 | $2.1bn | 14 | 21 |
| Q1 2026 | 12 | $1.8bn | 12 | 21 |
| Q2 2026 | 9 | $2.7bn | 8 | 21 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
MEDP and LLY →MEDP and JNJ →MEDP and VRTX →Choose a stock to compare with MEDP →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own MEDP, latest filings →Back to the 13F Explorer →